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Abstract: Concentration of hyaluronic acid (HA) in the lungs increases in idiopathic pulmonary
fibrosis (IPF). HA is involved in the organization of fibrin, fibronectin, and collagen. HA has been
proposed to be a biomarker of fibrosis and a potential target for antifibrotic therapy. Hyaluronidase
(HD) breaks down HA into fragments, but is a subject of rapid hydrolysis. A conjugate of poloxamer
hyaluronidase (pHD) was prepared using protein immobilization with ionizing radiation. In a model
of bleomycin-induced pulmonary fibrosis, pHD decreased the level of tissue IL-1β and TGF-β,
prevented the infiltration of the lung parenchyma by CD16+ cells, and reduced perivascular and
peribronchial inflammation. Simultaneously, a decrease in the concentrations of HA, hydroxyproline,
collagen 1, total soluble collagen, and the area of connective tissue in the lungs was observed. The
effects of pHD were significantly stronger compared to native HD which can be attributed to the
higher stability of pHD. Additional spiperone administration increased the anti-inflammatory and
antifibrotic effects of pHD and accelerated the regeneration of the damaged lung. The potentiating
effects of spiperone can be explained by the disruption of the dopamine-induced mobilization and
migration of fibroblast progenitor cells into the lungs and differentiation of lung mesenchymal stem
cells (MSC) into cells of stromal lines. Thus, a combination of pHD and spiperone may represent a
promising approach for the treatment of IPF and lung regeneration.
Keywords: idiopathic pulmonary fibrosis; hyaluronic acid; electron beam synthesis; poloxamer-
hyaluronidase; spiperone; transforming growth factor beta; extracellular matrix
1. Introduction
Hyaluronic acid (HA) is of great interest to the scientific and clinical community [1,2].
HA is present in body fluids, tissues, and in the extracellular matrix [3]. In the extracellular
matrix, hyaluronic acid performs a structural function by binding to cells and other compo-
nents of the extracellular matrix through specific and nonspecific interactions. Interacting
with proteoglycans, such as aggrecan and versican, HA participates in the organization of
fibrin, fibronectin, and collagen [3], and is also involved in the regulation of cell adhesion,
migration, and proliferation [1,3–5].
The course of radiation and bleomycin-induced fibrosis is characterized by a sig-
nificant increase in the concentration of HA in the lung parenchyma in animals [3,6,7]
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which is explained by tissue damage (destruction of epithelial cells) and inflammation [8,9].
HA plays an important role in regulating tissue injury and repair and controlling disease
outcomes in humans [3]. Thus, hyaluronic acid can act as a marker of fibrotic changes in
the lungs. On the other hand, HA is a convenient target for drug therapy.
The main enzyme that regulates the metabolism of HA is hyaluronidase (HD). By
cleaving HA into fragments, such as glucosamines and glucuronic acid, the enzyme digests
the extracellular matrix [10,11]. Intranasal administration of HD has been shown to reduce
the activity fibroblastic processes in the lungs of laboratory animals [6]. In this regard, HD
has been proposed to be a potential compound within antifibrotic therapy for idiopathic
pulmonary fibrosis.
Due to enzymatic hydrolysis, concentration of HD in the lungs rapidly decreases
2–3 min after administration. This leads to the restoration of the profibrotic viscosity of the
hyaluronan matrix and, therefore, to the progression of pulmonary fibrosis. To increase
the stability of HD, various forms of pegylated hyaluronidase have been developed [12].
HD conjugated with polyethylene glycol has greater physical stability, lower solubility,
reduced sensitivity to proteolytic enzymes, and lower immunogenicity compared to native
HD [13,14]. However, the pharmacological activity of pegylated hyaluronidase may be
inferior to that of native HD, and the pharmacological effects may not be stable [14].
This could be explained by a change in the structure of the hyaluronidase molecule after
conjugation with polyethylene glycol [14,15]. Pluronics, which are block copolymers of
polyoxyethylene and polyxypropylene, have been proposed as safe carriers for HD [15].
Under certain conditions, polymer nanoparticles form nanoaggregates (micelles), into
which drug molecules can be introduced. The micelle can be composed of a combination of
two pluronics or polyethylene glycol with pluronic [16]. Indeed, such structures are have
been used for targeted therapy [16–21]. We have previously studied the effects of conjugates
of pluronics with a predominance of hydrophobic properties and amphiphilic properties
with hyaluronidase [22]. Stable antifibrotic effects were mediated by a conjugate based on
hydrophobic Pluronic L31 with hyaluronidase (poloxamer-hyaluronidase or pHD).
In the present study, we aimed to evaluate the effects of poloxamer hyaluronidase on
bleomycin-induced alveolar damage, inflammation, and lung fibrosis in C57BL/6 mice in
comparison with native HD. In addition, we studied the effect of pHD on lung regeneration
and on mesenchymal cells as cells involved in fibrosis. Increasing the effectiveness of drug
treatment is an important clinical challenge in the treatment of patients with IPF. To enhance
the effects of pHD, we supplemented it with a spiperone, which itself has been proven as
an anti-fibrotic agent [23].
2. Results
2.1. Concentration of Hyaluronidase in the Lungs of Mice after a Single Intranasal Administration
of HD and pHD in Healthy Mice
After the introduction of native HD (group 1), we detected one phase of absorption
of hyaluronidase in the lungs for 1 min of observation, with a maximum concentration of
10 ng/mg. Furthermore, a rapid excretion of the substance from the lungs was observed
hyaluronidase in the lungs of mice of group 1 with HD levels of 0.5 ng/mg 20 after
application (Figure 1).
After intranasal pHD administration into the lungs, three phases of substance absorp-
tion were found (Figure 1). The first phase of hyaluronidase absorption ressembled that of
the group of mice which recieved native HD. However, the concentration of the substance
in group 2 was three times lower than in group 1. At 5 min, we observed a second phase of
absorption in group 2 with 5.13 ng/mL in the lung tissue. This could be explained by a
degradation of the least stable fraction of polymerosomes. The third phase is a degradation
of the stable fraction of polymerosomes by the reticulo-endothelial system of the lung
tissue and a release of hyaluronidase. The maximum concentration of hyaluronidase was
reached after 2 h with 7.32 ng/mg. Furthermore, a slow decrease in the concentration of
the substance in the lungs was observed within 2–8 h. Eight hours after the administration
of pHD, the concentration of hyaluronidase was 1.38 ng/mg.
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Figure 1. Hyaluronidase levels (standard error of the mean) in the lung. Pharmacokinetics of native
hyaluronidase (HD) and poloxamer-hyaluronidase (pHD) in the lung tissue of mice after a single
intranasal administration at a dose of 40 U/kg.
2.2. Concentration of Fibroblastic Process Molecules in Lungs Damaged by Bleomycin during
Treatment with pHD Monotherapy and in Combination with Spiperone
Figure 2 shows a graphical scheme of the protocol for inducing pulmonary fibrosis by
bleomycin and the protocol for studying the pHD.
Figure 2. Graphical scheme of the protocol for inducing pulmonary fibrosis by bleomycin and the protocol for studying pHD.
Groups: Intact control—Group 1; mice with bleomycin-induced pneumofibrosis—Group 2; mice with bleomycin-induced
pneumofibrosis treated HD—Group 3; mice with bleomycin-induced pneumofibrosis treated pHD—Group 4; mice with
bleomycin-induced pneumofibrosis treated Spiperone—Group 5; mice with bleomycin-induced pneumofibrosis treated
Spiperone+pHD—Group 6.
Modeling of pneumofibrosis caused an increase in the concentration of HA (by
3.57 times, p < 0.05), hydroxyproline (by 3.07 times, p < 0.05), type 1 collagen (by 1.99 times,
p < 0.05), and total soluble collagen (by 1.37 times, p < 0.05) in the lung homogenate of
group 2 mice compared with mice of intact control (group 1) (Figure 3). However, the
concentration of HD1 in group 2 (by 63.2%, p < 0.05) was lower than in group 1.
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Figure 3. The levels of hyaluronic acid (a), hydroxyproline (b), and collagen type I (c), total
soluble collagen (d), and hyaluronidase 1 (e) in homogenate of whole right lung lobes received
from male C57BL/6 mice (d21). Groups: Intact control; mice with bleomycin-induced pneumofi-
brosis (Pneumofibrosis); mice with pneumofibrosis treated HD (Pneumofibrosis+HD); mice with
pneumofibrosis treated pHD (Pneumofibrosis+pHD); mice with pneumofibrosis treated Spiperone
(Pneumofibrosis+Spiperone); mice with pneumofibrosis treated Spiperone+pHD (Pneumofibro-
sis+Spiperone+pHD). *—p < 0.05 significance of difference compared with intact control group;
• p < 0.05 significance of difference compared with the Pneumofibrosis group; #—p < 0.05 significance
of difference compared with the Pneumofibrosis+pHD group; —p < 0.05 significance of difference
compared with the Pneumofibrosis+Spiperone group.
HD treatment had positive effects on hydroxyproline and hyaluronidase 1 levels in
the lungs of group 3 mice compared to mice with pneumofibrosis. The effect of pHD
administration was superior to that of the HD. As shown in Figure 3, there was a significant
decrease in the concentration of hyaluronic acid (by 73.5%, p < 0.05), hydroxyproline (by
75%, p < 0.05), collagen type 1 (by 54.3%, p < 0.05), and total soluble collagen (by 30%,
p < 0.05) in group 4 compared to mice with pneumofibrosis. After administration of pHD,
the level of hyaluronidase in the lung homogenate increased 2-fold (p < 0.05) (Figure 3).
The effects of spiperone were similar to those of pHD. Specifically, the hyaluronidase
1 level increased and the level of hyaluronic acid, hydroxyproline, type 1 collagen, and
total collagen decreased. We did not observe a potentiation of the effects when spiperone
and pHD were co-administred in group 6 (Figure 3).
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2.3. Concentration of Pulmonary IL-1β, TGF-β, and TNF-α in Bleomycin-Damaged Lungs during
Monotherapy with pHD and Polytherapy with a Combination of Spiperone and pHD
After bleomycin administration an increase of IL-1β (by 60%, p < 0.05), TGF-β
(by 35.2%, p < 0.05), and TNF-α (by 80.2%, p < 0.05) levels was observed in lung ho-
mogenates from mice with bleomycin-induced pneumofibrosis compared with intact
controls (Figure 4). HD and pHD had no effect on IL-1β and TNF-α, but reduced the levels
of TGF-β in group 3 (by 80%, p <0.05) and group 4 (by 88.8%, p < 0.05) compared to mice
with pneumofibrosis. Monotherapy with spiperone and polytherapy with spiperone and
pHD significantly decreased the concentration of IL-1β (by 77.3% and 50.2%, respectively)
and TGF-β (48.2% and 66%, respectively) (Figure 4).
Figure 4. The levels of IL-1β, TGF-β, and TNF-α in lung homogenate received from male C57BL/6 mice (d21). Groups:
Intact control; mice with bleomycin-induced pneumofibrosis (Pneumofibrosis); mice with pneumofibrosis treated HD (Pneu-
mofibrosis+HD); mice with pneumofibrosis treated pHD (Pneumofibrosis+pHD); mice with pneumofibrosis treated Spiper-
one (Pneumofibrosis+Spiperone); mice with pneumofibrosis treated Spiperone+pHD (Pneumofibrosis+Spiperone+pHD).
*— p < 0.05 significance of difference compared with intact control group; • p < 0.05 significance of difference compared
with the Pneumofibrosis group; #— p < 0.05 significance of difference compared with the Pneumofibrosis+pHD group;
—p < 0.05 significance of difference compared with the Pneumofibrosis+Spiperone group.
2.4. Histological Parameters of the Lungs Damaged by Bleomycin after Monotherapy with pHD
and a Combination of Spiperone and pHD
2.4.1. Effects of HD, pHD, and Spiperone on Tissue Morphology
Staining of lung preparations with hematoxylin and eosin revealed decreased numbers
of inflammatory cells, such as lymphocytes, neutrophils, and plasma cells, in the lung
parenchyma in mice with pneumofibrosis in group 4 compared to untreated mice from
group 2 (Figure 5). A small number of inflammatory cells was observed around the vessels
and bronchioles. In group 3 (HD), there was a less significant decrease in the number of
inflammatory cells in the lung parenchyma compared to group 4 mice. In this group, the
inflammatory infiltrate around the vessels and bronchioles remained at the level of mice
with pneumofibrosis.
Treatment of pulmonary fibrosis with spiperone reduced the infiltration of lympho-
cytes, neutrophils, and plasma cells into the lungs of group 5 mice compared to untreated
mice with pneumofibrosis (Figure 5). In mice treated with spiperone, there was no venous
congestion and similar levels of hemorrhages as in animals of group 2.
Sequential administration of spiperone and pHD reduced the activity of the inflamma-
tory response in the lungs of mice in group 6 more efficiently compared with monotherapy
in groups 4 and 5 (Figure 5). Polytherapy led to a complete resolution of the inflammatory
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reaction in the lung parenchyma around the vessels and bronchioles. Moreover, no venous
congestion and hemorrhages were observed.
Figure 5. Photomicrographs of left lung sections (middle pulmonary field) obtained from male C57BL/6 mice on d21.
Groups: Intact control; mice with bleomycin-induced pneumofibrosis (Pneumofibrosis); mice with bleomycin-induced
pneumofibrosis treated HD (Pneumofibrosis+HD); mice with bleomycin-induced pneumofibrosis treated pHD (Pneu-
mofibrosis+pHD); mice with bleomycin-induced pneumofibrosis treated Spiperone (Pneumofibrosis+Spiperone); mice
with bleomycin-induced pneumofibrosis treated Spiperone+pHD (Pneumofibrosis+Spiperone+pHD). Tissues stained with
hematoxylin-eosin, scale bar 50 µm.
2.4.2. Evaluation of Collagen Fibers
Van Gieson staining of lung preparations with picrofuchsin revealed a significant
decrease in the area of connective tissue (by 52%, p < 0.05) in the lungs of mice in group 4
after administration of pHD compared to mice in group 2 (Figure 6, Figures S1 and S2). In
contrast, in group 2, native HD had no effect on connective tissue in the lungs.
Spiperone prevented the deposition of connective tissue in the lungs of mice in group
5 compared to mice in group 2 (decreased of 48.8%, p < 0.05) (Figure 6, Figures S1 and S2).
Polytherapy with spiperone and pHD resulted in a significantly higher decrease of the area
of connective tissue in mice of group 6 compared to animals that underwent monotherapies
with spiperone (group 5) and pHD (group 4). The area of connective tissue in group 6 was
32.5% (p < 0.05) relative to group of mice with pneumofibrosis.
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Figure 6. Photomicrographs of left lung sections (middle pulmonary field) obtained from male C57BL/6 mice on d21
(a). Groups: Intact control; mice with bleomycin-induced pneumofibrosis (Pneumofibrosis); mice with bleomycin-induced
pneumofibrosis treated HD (Pneumofibrosis+HD); mice with bleomycin-induced pneumofibrosis treated pHD (Pneu-
mofibrosis+pHD); mice with bleomycin-induced pneumofibrosis treated Spiperone (Pneumofibrosis+Spiperone); mice
with bleomycin-induced pneumofibrosis treated Spiperone+pHD (Pneumofibrosis+Spiperone+pHD). Tissues stained by
Van Gieson, scale bar 50 µm. Content of the connective tissue in the lungs of C57BL/6 mice with bleomycin-induced
pneumofibrosis on d21 (b). Content of the connective tissue in the lungs was expressed as a percentage of the lung tissue
area. *—p < 0.05 significance of difference compared with intact control group; • p < 0.05 significance of difference compared
with the Pneumofibrosis group; #—p < 0.05 significance of difference compared with the Pneumofibrosis+pHD group;
—p < 0.05 significance of difference compared with the Pneumofibrosis+Spiperone group.
2.5. Influence of Spiperone and pHD on the Expression of CD16, CD31, and Pan-Cytokeratin in
Bleomycin-Damaged Lungs
Immunohistochemical analysis of lung preparations revealed a decrease in the ex-
pression of the inflammatory cell marker CD16 in the lungs of mice with pneumofibrosis
when treated with spiperone (by 60%, p < 0.05) and pHD (by 44%, p < 0.05) compared with
untreated mice of group 2 (Figure 7). The effects of spiperone and pHD were extended to
predominantly diffuse expression of CD16. The effects on perivascular and peribronchial
marker expression were negligible.
Spiperone increased the expression of CD31 (by 64.4%, p < 0.05) and pan-cytokeratin
(by 18%, p < 0.05) in the lung tissue of group 4 mice relative to group 2 mice. The effects of
spiperone increased the expression of CD31 in the alveoli and the lumen of blood vessels.
pHD had no effect on CD31+ cells and pan-cytokeratin+ cells in group 4 (Figure 7).
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Figure 7. Micrographs of lung sections (middle pulmonary field) obtained from male C57BL/6 mice. Immunohistochemical
staining (brown) for specific cell markers: CD16, CD31, and pan-cytokeratin (AE1/AE3) in the lungs of C57BL/6 mice
(a). Scale bar 10 µm. Relative percentages of cells expressing CD16, CD31, and pan-cytokeratin (AE1/AE3) in the lungs of
control mice (Intact control), mice with bleomycin-induced pneumofibrosis (Pneumofibrosis); mice with bleomycin-induced
pneumofibrosis treated pHD (Pneumofibrosis+pHD); mice with bleomycin-induced pneumofibrosis treated Spiperone
(Pneumofibrosis+Spiperone) assessed by immunohistochemical on d21 (b). *—p < 0.05 significance of difference compared
with intact control group; • p < 0.05 significance of difference compared with the Pneumofibrosis+pHD group.
2.6. Cytometric Evaluation of Mesenchymal Stem Cells in Bleomycin-Damaged Lungs during
Treatment with pHD and Spiperone
Bleomycin injection led to an increase of the number of mesenchymal stem cells (MSC)
in the lungs of mice with pneumofibrosis (by 51%, p < 0.05) compared to intact contol mice
(Figure 8). HD had no effect on MSCs in group 3. After administration of pHD, the number
of MSCs in group 4 (by 80%, p < 0.05) was higher than in group 2. Spiperone monotherapy
and polytherapy with spiperone and pHD, on the contrary, reduced the number of MSCs
in the lungs of mice in group 5 (by 37%, p < 0.05) and group 6 (by 39.2%, p < 0.05) compared
with untreated mice with pneumofibrosis.
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Figure 8. Characterization of MSCs cell population isolated from lung of male C57BL/6 mice
on d21. Cells were analyzed by flow cytometry using antibodies for mouse CD45, CD44, CD73,
CD90 and CD106. (a) Quantification showing mean values from three independent experiments.
(b–d) Representative dot plots. Groups: Intact control; mice with bleomycin-induced pneumofi-
brosis (Pneumofibrosis); mice with bleomycin-induced pneumofibrosis treated HD (Pneumofibro-
sis+HD); mice with bleomycin-induced pneumofibrosis treated pHD (Pneumofibrosis+pHD); mice
with bleomycin-induced pneumofibrosis treated Spiperone (Pneumofibrosis+Spiperone); mice with
bleomycin-induced pneumofibrosis treated Spiperone+pHD (Pneumofibrosis+Spiperone+pHD).
*— p < 0.05 significance of difference compared with intact control group; • p < 0.05 significance of
difference compared with the Pneumofibrosis group; # —p < 0.05 significance of difference compared
with the Pneumofibrosis+pHD group.
2.7. Cell Culture Studies
2.7.1. Influence of Spiperone, HD, and pHD on CFU-F
As shown in Figure 9, the clonal activity of fibroblast progenitor cells increased
significantly, primarily in the culture of bone marrow CD45 cells (d3, d7). At later stages,
an increase in the number of CFU-F was observed in the culture of blood CD45- cells (d7,
d21) and lung CD45- cells (d7, d14, d21).
The main effects of the drugs were observed on d14 and d21. Thus, pHD did not affect
the clonal activity of fibroblast progenitor cells in the bone marrow and blood. On the other
hand, treatment reduced the number of CFU-F (by 56%, p < 0.05 compared with group of
mice with pneumofibrosis) in the lung cell culture on d21 (Figure 9).
Spiperone had a suppressive effect on the growth of CFU-F in the culture of fibroblast
progenitor cells isolated from bone marrow (d3, d21), blood (d21), and lung (d7, d14) of
group 5 compared with group of mice with pneumofibrosis (Figure 9).
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Figure 9. Photomicrographs of culture of fibroblast progenitor cells isolated from lung (a,d); bone marrow (b,e); and
blood (c,f) male C57BL/6 mice of intact control. Native culture (a–c) and culture stained with hematoxylin-eosin (d–f).
100× Clonal activity of CD45- fibroblast progenitor cells (CFU-F, ×105 adherent mononuclear cells) isolated from lung
(g), bone marrow (h), and blood (i) of male C57BL/6 mice after bleomycin introduction. Groups: Intact control; mice
with bleomycin-induced pneumofibrosis (Pneumofibrosis); mice with bleomycin-induced pneumofibrosis treated pHD
(Pneumofibrosis+pHD); mice with bleomycin-induced pneumofibrosis treated Spiperone (Pneumofibrosis+Spiperone);
mice with bleomycin-induced pneumofibrosis treated Spiperone+pHD (Pneumofibrosis+Spiperone+pHD). *—p < 0.05
significance of difference compared with intact control group; • p < 0.05 significance of difference compared with the
Pneumofibrosis group.
Fibroblast progenitor cells isolated from the bone marrow and blood of group 6 mice
on d14 and d21 generated the same number of colonies as the corresponding cells in
group 4 mice (Figure 9). However, the clonal activity of fibroblast progenitor cells of the
lungs of group 6 was significantly lower than in group 2 on the d14 and d21, and was
comparable with group 5 on the d14 and with group 4 on the d21.
2.7.2. Multilineage Differentiation of MSCs
Pulmonary fibrosis did not affect the chondrogenic and adipogenic differentiation
of MSCs in group of mice with pneumofibrosis (group 2) compared with group 1 at the
time of the highest content of connective tissue in the lungs (d21) (Figure S3). At the same
time, we observed a decrease (by 78%, p < 0.05) in the area of mineralized areas (osteogenic
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differentiation) (Figure S1) and an increase (by 52%, p < 0.05) in the number of fibroblasts
in the corresponding cultures of group 2 (Figure 10).
Figure 10. Photomicrographs of fibroblast differentiation of of primary culture adherent cells isolated
from the lungs of C57BL/6 mice from groups: Intact control (a); mice with bleomycin-induced
pneumofibrosis (Pneumofibrosis) (b); mice with bleomycin-induced pneumofibrosis treated Spiper-
one (Pneumofibrosis+Spiperone) 100× (c). The presence of fibroblasts in culture was confirmed by
staining blue by May-Grunwald. Fibroblast differentiation (d). The ordinate axis: fibroblasts (% of
total number of mononuclears) (d). *—p < 0.05 significance of difference compared with intact control
group; • p < 0.05 significance of difference compared with the Pneumofibrosis group.
After spiperone treatment, the number of mesenchymal cells with lipophilic inclusions
in group 5 was significantly lower (by 72%, p < 0.05) than in group 2 (Figure S3). In addition,
relative to group 2, spiperone had an inhibitory effect on adipogenic, chondrogenic, and
fibroblastic differentiation of MSCs. In the first case, in vitro, the number of cells containing
lipid inclusions decreased by 63.7% (p < 0.05), in the second case, the number of cells
containing sulfated proteoglycans decreased by 34% (p < 0.05), in the third case, the content
of fibroblasts decreased by 36.7% (p < 0.05) (Figure 10).
3. Discussion
IPF is a chronic progressive disease. IPF is characterized by a development of intersti-
tial fibrosis and progressive respiratory failure [24,25]. IPF prognosis is poor and the life
expectancy after diagnosis is five years [26,27]. The lack of effective treatment in patients
with IPF predetermined the present study. Hyaluronidase has been proposed as a molecule
with potential therapeutic activity. HD is the main enzyme that regulates the metabolism of
hyaluronic acid. By cleaving HA into glucosamines and glucuronic acid, HD remodulates
the extracellular matrix [10,11]. In experimental pulmonary fibrosis, hyaluronidase reduces
the concentration of glucuronic acid and thus prevents the development of fibrosis [6].
However, due to enzymatic hydrolysis, the concentration of HD in the lungs rapidly de-
creases. This leads to the restoration of the profibrotic viscosity of the hyaluronan matrix
and the progression of pulmonary fibrosis.
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To deliver a pharmacologically active molecule to the target and prevent its hydrolysis
in an aggressive environment, the use of Pluronic has been suggested [14,16]. Similar
structures are used for targeted therapy [14,16,19–21]. We have studied the conjugate of
Pluronic L31 and hyaluronidase 1 as a potential therapeutic agent for the treatment of
pulmonary fibrosis. With the help of electron beam exposure, a polymer micelle with an
incorporated enzyme was formed.
In the first part of this study, we revealed a significantly greater stability of pHD in
comparison with native HD with intranasal administration. Five minutes after intranasal
administration of HD, traces of the enzyme were found in the lungs. After intranasal
administration of pHD, three phases of degradation were observed (Figure 1). The third
phase of the degradation of pHD was the longest: within 2–8 h, a slow decrease in the
concentration of the substance in the lungs was observed. The maximum value of the
concentration of hyaluronidase was reached after 2 h of observation.
The second part of the study is devoted to the study of the effects of pHD in compari-
son with HD in a model of pulmonary fibrosis on the 21st day of the experiment. In mice
treated with pHD (group 4), a complete resolution of the inflammatory response in the
lung tissue was observed with only a small number of inflammatory cells present around
the vessels and bronchioles (Figure 5). The HD administration group of mice retained a
larger number of inflammatory cells in the lung parenchyma compared to mice treated
with pHD, peribronchial, and perivascular inflammation persisted (Figure S4). pHD sig-
nificantly reduced the fibrotic response to bleomycin injury of the alveolar epithelium.
The content of connective tissue in the lungs decreased by more than 2-fold in relation to
group of mice with bleomycin-induced pneumofibrosis (Figure 6). In addition, therapy
with pHD decreased the concentrations of TGF-β, hydroxyproline, collagen type 1, and
total collagen in the lung homogenate. Moreover, it induced a sharp decrease in the ratio
of hyaluronic acid/hyaluronidase 1 to 0.24 at 0.33 in group of intact control and 3.24 in
group of mice with pneumofibrosis. HD did not significantly affect most of these parame-
ters. Additionally, immunohistochemistry was carried out to assess the regeneration of
epithelial and endothelial cells. We did not observe significant changes in the expression of
CD31 and pan-cytokeratin in the lungs of mice in group 4 relative to group of mice with
bleomycin-induced pneumofibrosis.
According to previous reports, polymersomes are adsorbed on the basal and cell
membranes [17]. However, changes in the physicochemical properties of membranes, such
as viscosity and permeability after which the degradation of the polymerosome occur [28].
The pHD conjugates studied in this work are about 100 nm in size. Particles of this size are
called the “respirable fraction” and have the maximum pharmacological effect, since they
penetrate without destruction into the alveoli, where, after degradation of the polymer
carrier, hyaluronidase re-modulates the hyaluronan matrix.
We have previously demonstrated the anti-inflammatory and anti-fibrotic effects of
spiperone [23]. We hypothesized that co-administration of spiperone and pHD could have
higher therapeutic efficacy compared to a monotherapy with each respective compound.
According to our data, spiperone reduces the edema of the alveolar epithelium,
exudation, and infiltration of the lung parenchyma, walls, and lumen of the alveoli by
inflammatory cells, including CD16+ cells, in group 5 compared with mice in group 2
(d21). Simultaneously, a decrease in the degree of desquamation of alveocytes in the lumen
of the alveoli has been observed. As a result, no obliteration of the alveoli occurs, and
the destruction of lung tissue slows down. In addition, the lung preparations of group
5 lack cysts, which were typical for group 2 (Figure 5). The area of connective tissue in
the lungs of mice treated with spiperone was 50% (p < 0.05) lower than in untreated mice.
In confirmation of the anti-inflammatory and antifibrotic activity of spiperone, ELISA
data indicated a decrease in the expression of inflammation and fibrosis factors (IL-1β,
TGF-β) and fibrogenesis molecules, such as hydroxyproline, type 1 collagen, total collagen,
in the lungs. As mentioned earlier, destruction of the profibrotic hyaluronic matrix is
particularly important for anti-fibrotic therapy. Spiperone shifted the ratio of hyaluronic
Int. J. Mol. Sci. 2021, 22, 5599 13 of 22
acid/hyaluronidase 1 towards the enzyme: in group 5 this ratio is 0.71, at 3.24 in group 2,
and 0.33 in group 1. This is noteworthy, since dopamine control is assumed to at least partly
control the metabolism of hyaluronic acid and hyaluronidase. However, an interaction
of the D2 signaling pathway with hyaluronidase 1 and hyaluronic acid in experimental
fibrosis has not been described before.
In lung fibrosis, restoration of damaged tissues and cells is one of the important
criteria for the effectiveness of the treatment. According to our data, spiperone increased
the expression of epithelial markers (pan-cytokeratin) and endothelium (CD31) in the
lung parenchyma of group 5 mice compared to group 2 (Figure 7). These results indicate
regeneration of bleomycin-damaged lung tissue. In this regard, implication of blockade of
dopamine D2 receptors in IPF therapy is significantly increasing.
Since mesenchymal cells participate to the development of pulmonary fibrosis [29–31],
we assessed the effects of spiperone on these cell populations. Spiperone significantly
reduced the population of MSCs in the lungs of mice in group 5 compared with group 2
on the 21st day of the experiment (Figure 9). At the same time, a decrease in the activity
of MSC differentiation into adipocytes, osteoblasts, chondrocytes, and fibrocytes was
observed. Notably, cells such as fibrocytes produce collagen [31]. Another important aspect
of the action of spiperone is associated with a decrease in the clonal activity of fibroblast
progenitor cells in the following chronological order: in the bone marrow, blood, lungs
(Figure 10 and Figure S1). All these data suggest dopamine regulation of various functions,
such as mobilization, migration, proliferation, and differentiation, of mesenchymal cells
and inhibition of these processes by spiperone.
Next, we studied the effects of sequential administration of spiperone and pHD
(polytherapy) in the simulation of pulmonary fibrosis (d21). Polytherapy prevented the
infiltration of the parenchyma and alveoli by inflammatory cells (lymphocytes, neutrophils,
plasma cells), a significantly smaller number of inflammatory cells were localized around
the vessels and bronchioles than with spiperone monotherapy and pHD (Figure 5). In the
walls of the alveoli in animals of group of mice with pneumofibrosis and treated spiperone
and pHD, there was no venous plethora and hemorrhages. These data can be interpreted as
an absence of inflammatory reaction in the lung tissue. In group 6, the decrease in the level
of tissue IL-1β was greater than in group 4, but less prominent than in group 5 (Figure 4).
However, an opposite pattern was observed for TGF-β.
Polytherapy inhibited the synthesis and deposition of collagen in the bleomycin-
damaged lungs more intensely than monotherapy with pHD or spiperone. Figure 3 shows
that the sequential administration of drugs reduced the concentration of fibrogenesis
molecules. In mice with pulmonary fibrosis treated with spiperone and pHD, the content of
connective tissue did not significantly differ from that in group of mice from intact control,
and the value of the ratio hyaluronic acid/hyaluronidase 1 decreased to 0.43. We did not
observe similar effect after a monotherapy.
The data presented in this study indicate that prescribing D2 dopamine receptor an-
tagonists the subsequent destruction of the profibrotic matrix of hyaluronan by poloxamer
hyaluronidase resistant to the action of enzymatic factors might represent a new therapeutic
avenue to treatment of IPF. Notably, the proposed approach could lead to a regeneration of
damaged and lost endothelial and epithelial cells in patients with IPF.
4. Materials and Methods
4.1. Animals
Nine-week-old male C57BL/6 mice (Surgical Bio-modelling Department of the Gold-
berg ED Research Institute of Pharmacology and Regenerative Medicine, Tomsk, Russia)
were used in all experiments. Animals were randomly assigned into the experimental
groups. All experimental protocols were approved by the animal care and use committee
of the Goldberg ED Research Institute of Pharmacology and Regenerative Medicine, Tomsk
NRMC (IACUC Protocol No. 94092015, 17.09.2015). Within this study, 210 mice were used.
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4.2. Modeling of Experimental Pulmonary Fibrosis
Experimental pulmonary fibrosis was induced by a single intratracheal bleomycin
(BLM, Nippon Kayaku Co., Ltd., Tokyo, Japan) administration at a dose 80 µg/mouse in
0.03 mL of 0.9% NaCl, which was slowly instilled in the tracheal lumen [32]. All procedures
were performed under anesthesia induced by inhalation of isoflurane using an apparatus
for inhalation anesthesia UGO BASILE model 21050 (UGO BASILE, Comerio, Italy). These
animals formed the BLM control. Control animals were administered a single intratracheal
0.03 mL 0.9% NaCl. The introduction of BLM was defined as day zero (d0). All mice were
euthanized on d21 by CO2.
Mice were cohoused (five to six mice per cage) and entrained to a reverse 12 h light/12 h




Bull testicular hyaluronidase (HD) was kindly provided for research by LLC Scientific
Future Management (Novosibirsk, Russia). In stage 1 of the experiment, HD (40 U/kg)
in a volume 8 µL buffer/mouse was administered intranasally once. During the 2nd and
3rd stages of the experiment, HD was administered intranasally at a dose of 40 U/kg in a
volume of 8 µL buffer/mouse once a day on days 10–18 of the experiment.
4.3.2. Poloxamer Hyaluronidase
The drug for the study is a conjugate of a polymer carrier Pluronic L31 (predomi-
nance of hydrophobic properties) and testicular hyaluronidase (hyaluronidase 1, provided
for research by LLC Scientific Future Management (Novosibirsk, Russia): poloxamer-
hyaluronidase (pHD). During the 1st stage of the study, mice were injected with pHD at a
dose of 40 U/kg intranasally in a volume of 8 µL/mouse PBS once. During the 2nd and
3rd stages of the study, mice were received pHD at a dose of 40 U/kg intranasally in a
volume of 8 µL/mouse PBS once a day on days 10–18 of the experiment.
4.3.3. Spiperone
Selective, competitive antagonist of dopamine D2-receptors spiperone was obtained
from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, USA). During monotherapy, spiperone
was injected intraperitoneally at a dose of 1.5 mg/kg in 100 µL of physiological saline
once a day on days 10–18 of the experiment. During polytherapy, spiperone was injected
intraperitoneally at a dose of 1.5 mg/kg in 100 µL of physiological saline once a day on
days 10–18 of the experiment, 1 hour before the pHD introduction.
4.4. Study Design and Experimental Groups
At the first stage of the study, the concentration of hyaluronidase in the lung ho-
mogenate in mice after a single intranasal administration of HD and pHD was evaluated
using ELISA. The mice were allocated into two groups (n = 45/group): group 1 (mice
treated with HD; group 2 (mice treated with pHD). Blood samples were taken 1 h before
administration (0 min) and after 1, 5, 10, 20, and 40 min and after 1; 2; 4; and 8 h after the
introduction of HD and pHD (Figure 11).
The second stage of the study was devoted to the study of the effects of native
hyaluronidase and pHD on a bleomycin-induced pneumofibrosis model (Figure 2). In
addition, the possibility of enhancing the effects of pHD with spiperone has been studied.
The mice were allocated into 6 equal groups (n = 10/group): intact control is group 1, which
is mice without bleomycin and those treated with the solvent made up the control group;
pneumofibrosis is in group 2, which is mice receiving bleomycin; pneumofibrosis+HD
are in group 3, which is pneumofibrosis, treated with HD; pneumofibrosis + pHD are in
group 4, which is pneumofibrosis treated with pHD; pneumofibrosis + spiperone are in
group 5, which is pneumofibrosis treated with spiperone; pneumofibrosis + spiperone
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+ pHD are in group 6, which is pneumofibrosis treated with spiperone and pHD. On
the 21st day of the experiment, inflammation, connective tissue, and lung damage were
histologically evaluated in mice of groups 1–6; ELISA levels of IL-1β, TGF-β, TNF-α, type I
collagen, hydroxyproline, and hyaluronic acid in the lung homogenate.
Figure 11. Graphical scheme of the protocol for studying the pharmacokinetics of native
hyaluronidase and poloxamer-hyaluronidase in the lung tissue of mice after a single intranasal
administration at a dose of 40 U/kg.
During the third stage, the effect of spiperone and pHD on MSCs and fibroblast
progenitor cells was studied using a pneumofibrosis model. The mice were allocated
into 5 groups (n = 10/group): intact control is group 1, which is mice without bleomycin
and those treated with solvent made up the control group; pulmonary fibrosis is group 2,
which is mice receiving bleomycin; pulmonary fibrosis + pHD are in group 4, which is
pulmonary fibrosis, treated with pHD; pulmonary fibrosis + spiperone are in group 5,
which is pulmonary fibrosis treated with spiperone; pneumofibrosis + spiperone + pHD are
in group 6, which is pulmonary fibrosis treated with spiperone and pHD. On the 21st day
of the experiment, the content of lung MSCs, the content and clonal activity of fibroblast
progenitor cells of the lungs were assessed by cytometric and cultural methods in mice
of groups 1, 2, 4–6, the differentiation of lung MSCs was studied in mice of groups 1, 2,
and 5 (Figure 12).
Figure 12. Graphical scheme of the protocol for studying the effect of spiperone and pHD on MSCs
and fibroblast progenitor cells.
4.5. Enzyme-Linked Immunosorbent Assay
4.5.1. Hyaluronate-endo-β-N-acetylhexosaminidase Measurement
The hyaluronoglucosaminidase 1 (HYAL1) or hyaluronidase (HD) level in lung ho-
mogenate of right lung lobes was determined by ELISA according to manufacturer instruc-
tions (Bovine Hyaluronidase-1 (HYAL1) ELISA kit, MBS7238849, MyBioSource, Inc., San
Diego, CA, USA). The right lung lobes were excised and snap frozen after having measured
the wet weight. Sensitivity was >0.1 ng/mL.
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4.5.2. IL-1β, TGF-β, TNF-α Measurements
The concentrations of IL-1β, TNF-α, and TGF-β in lung homogenate of right lung
lobes were determined by ELISA according to manufacturer instructions (Cusabio Biotech
CO., Ltd., Wuhan, China). Sensitivities were >7.8 pg/mL for IL-1β, >4.7 pg/mL for TNF-α,
and >0.2 ng/mL for TGF-β.
4.5.3. Hyaluronic Acid, Hydroxyproline, Collagen Type I, and Total Soluble
Collagen Measurements
Hyaluronic acid, hydroxyproline, and collagen type I levels were determined by ELISA
according to the manufacturer instructions (Cusabio Biotech CO., Ltd, Wuhan, China).
Right lobes of the lung were isolated, weighed, and frozen immediately. Sensitivities were
>15.6 pg/mL for hyaluronic acid, >1.95 ng/mL for hydroxyproline, >0.039 ng/mL for
collagen type I. Results were expressed as ng (pg) per right lung.
The total soluble collagen was determined using a standard curve for the SircolTM
assay (S1000, Biocolor Ltd., Country Antrim, UK) according to the manufacturer’s in-
structions. The right lung lobes homogenate supernatants were placed in 1.5 mL tubes.
Sircol-dye was added, the content of the tubes homogenized for 30 min and centrifuged
for 10 min (10,000× g). The pellets were dissolved with alkaline reagent. Absorbance was
read at 540 nm. Detection Limit: 1.0 µg. The amount of total soluble collagen per whole
right lung was measurement. Results were expressed as µg collagen per mL.
4.6. Histological Examination of Lung Tissue
4.6.1. Analysis of Lung Tissue
The morphological examination of lungs was performed on d21. For histological
studies, left lung lobes were fixed in 4% neutral formalin solution, embedded in paraffin,
and sections with thickness of 5 µm were prepared. Subsequently, sections were staining
with hematoxylin and eosin. Histological examination was carried out in three areas of
lung tissue (upper, middle, and lower) on d21 as described previously [33]. Lung structure,
presence of edema, infiltration by proinflammatory cells as well as venous hyperemia, and
vascular and bronchial walls thickening were assessed [34–36]. Micropreparations from
each experimental animal were examined under the light microscope Axio Lab.A1 (Carl
Zeiss, MicroImaging GmbH; Göttingen, Germany) at 100× and 400×magnifications.
4.6.2. Analysis of Pulmonary Inflammation
The degrees of peribronchial and perivascular infiltrates were assessed by the scale of
inflammation and quantitative assessment of peribronchial and perivascular mononuclear
cells [37]. The drugs were coded and peribronchial inflammation was assessed in a blinded
manner using a reproducible scoring system. Each tissue slice was assigned a value from 0
to 3. A value of 0 was taken when no inflammation was detected, a value of 1 was when
there was a rare encounter with inflammatory cells, a value of 2 was when most of the
bronchi or vessels were surrounded by a thin layer (from one to five cells) of inflammatory
cells, and a value of 3 was when most of the bronchi and blood vessels were surrounded
by a thick layer (more than five cells) of inflammatory cells. Since there were five to seven
randomly selected tissue sections per mouse, inflammation scores could be expressed as
an average per animal and compared between groups.
In addition, cells in the peribronchial and perivascular segments were counted relative
to the length of the basement membrane. The total index of bronchial and vascular inflam-
mation was expressed as the number of inflammatory cells/µm of the basement membrane.
4.6.3. Analysis of Pulmonary Fibrosis
To count collagen fibers in lung parenchyma, the histological slides were stained by
picrofuchsin using the Van Gieson method [38,39]. At least 10 photomicrographs without
overlapping across the cut surface of the lung tissue at 100×magnification were taken for
each experimental animal. The used system consisted of a microscope (Axio Lab.A1, Carl
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Zeiss MicroImaging GmbH; Göttingen, Germany) with a video camera (AxioCam ERc5s,
Carl Zeiss; Göttingen, Germany), connected to a personal computer. Gathered images
were processed using the software AxioVision Rel.4.8.2. The content of collagen fibers
in lung was determined using a function for counting the area of the object in the image.
Bronchovascular strands were carefully removed from the analyzed areas. The count of
collagen fibers (X) was calculated using the formula:
X = Σ a × 100/(S - Σ b), (1)
where ∑ a is the sum of the pixels occupied by tissue with fibrosis in 10 images of one
specimen, S is the number of pixels corresponding to the full area of the image (when using
this camera and the program—4423680), b is the sum of pixels occupied by the empty part
of the slide, in 10 images one drug [38,39]. Content of the connective tissue in the lungs
was expressed as a percentage of the lung tissue area.
4.7. Immunohistochemical Examination of the Lungs
Immunohistochemical examination of the lungs was performed on d21. Sections of
lung tissue were placed on glass slides with an adhesive polylysin coating (Leica BioSys-
tems, Wetzlar, Germany). Before staining, tissue sections were dewaxed with the following
antigen unmasking in a citrate buffer (pH = 6) for 20 min. Incubation with primary antibod-
ies was performed in a wet chamber at 37 ◦C. The following primary markers were used
to identify specific cell markers antibodies: polyclonal antibodies to membrane protein
CD31 (ab28364, Abcam, Cambridge, MA, USA), monoclonal antibodies to CD16 (ab198169,
Cambridge, MA, USA), monoclonal antibodies to pan-cytokeratin (AE1/AE3) (ab80826,
Abcam, Cambridge, MA, USA). For antibody detection, an imaging system was used in
accordance with the manufacturer’s instructions (Spring Bioscience, Pleasanton, CA, USA).
The contrast of the sections was performed with hematoxylin. After staining, the slices
were dehydrated in xylene and enclosed in the installer environment. The microscope
Axio Lab.A1 (Carl Zeiss, MicroImaging GmbH; Göttingen, Germany) with the AxioCam
ERc5s camera (Carl Zeiss, Göttingen, Germany) was used to obtain micrographs. The
specimens were scanned randomly in their entirety without choosing the same field more
than once, by the sequential movement of the mechanical stage (10 micrographs for one
slice). The analysis of the obtained images and the counting of cells expressing detectable
antigens were performed using the ImageJ program (Madison, WI, USA), which quantified
the number of positive cells at 100×magnification [40,41].
4.8. Flow Cytometric Analysis
Mononuclear cells from lungs were isolated as described earlier [42] and the expression
of surface markers on mononuclear cells derived from lungs was analyzed. Fc-receptors
were blocked by pre-incubation of the cells with unconjugated anti-CD16/CD32 antibodies
for 10 min (eBioscience, San Diego, CA, USA, Clone: 93, Cat# 14-0161-85, 1/50 dilution)
in 50 µL of 0.1% saponin (Sigma-Aldrich, St. Louis, MO, USA, Cat# S4521) and 1% BSA
(Sigma-Aldrich, St. Louis, MO, USA, Cat# A3059-100G) in phosphate buffered saline
(PBS) per tube. After the pre-incubation, cells suspensions were stained with fluorophore-
conjugated monoclonal antibodies: CD45 PerCP (QC Testing: Mouse, Clone: 30-F11,
Cat# 557235, 1/100 dilution) or CD45 APC-Cy 7 (QC Testing: Mouse, Clone: 30-F11, Cat#
557659, 1/100 dilution), CD31 APC (QC Testing: Mouse, Clone: MEC 13.3, Cat# 551262,
1/50 dilution), CD34 FITC (QC Testing: Mouse, Clone: RAM34, Cat# 560238, 1/50 dilution),
CD73 V450 (QC Testing: Mouse, Clone: TY/23, Cat# 561544, 1/50), CD44 APC (QC Testing:
Mouse, Clone: IM7, Cat# 559250, 1/50), CD90 PerCP (QC Testing: Mouse, Clone: OX-7,
Cat# 557266, 1/50), CD106 (VCAM-1) FITC (QC Testing: Mouse, Clone: 429 (MVCAM.A),
Cat# 561678, 1/50) (all Becton Dickinson, San Jose, CA, USA). All antibodies were titrated
to determine their optimal staining concentration and appropriate isotype controls were
used. Labeled cells were washed thoroughly with 500 µL of FACSFlow (Becton Dickenson,
Franklin Lakes, NJ, USA, Cat# 342003).
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All samples were run on a Becton Dickenson FACSCanto II flow cytometer. The
instrument was set up and standardized using BD Cytometer Setup and Tracking (CS&T)
procedures according to manufacturer specifications. One hundred thousand events per
tube were acquired. Data were analyzed using FACSDiva 8.0 software.
Thus, mesenchymal stem cells were characterized as CD45- CD106+CD44+CD73+CD90+,
fibroblast progenitor cells as CD45-CD31-CD34+CD90+.
4.9. In Vitro Study of MSCs and Fibroblast Progenitor Cells of the Lungs
4.9.1. Isolation of Lung Cells
The chest cavity was surgically opened under sterile conditions. All metal instruments
were sterilized by autoclaving; sterile disposables were from BD Falcon. Lungs were
isolated from surrounding tissue, rinsed with phosphate buffered saline (PBS, Sigma-
Aldrich, St. Louis, MO, USA), mechanically dispersed, and minced with scissors. Blood
was washed out of the lungs by perfusion of the right ventricle of the heart using 3–5 mL
of chilled Hanks’s phosphate buffer (HBSS, Sigma-Aldrich, St. Louis, MO, USA). In a Petri
dish with a diameter of 90 mm with HBSS, the trachea and large bronchi were removed.
Next, the tissue was minced using disposable scalpels, with a sufficient volume of liquid,
and treated with a 0.2% collagenase II type (Sigma-Aldrich, St. Louis, MO, USA) solution,
diluted with sterile HBSS, preheated to 37 ◦C. The mixture was then incubated at 37 ◦C
for 30 min. To remove the stroma and large aggregates, the cell suspension was filtered
through a 70 µm nylon cell filter (BD Falcon, Franklin Lakes, NJ, USA). The cell suspension
was centrifuged for 10 min at 300× g and the supernatant was discarded. Carefully the
precipitation was resuspended, using 2 mL of cold medium of the following composition:
90% DMEM-LG, 10% inactivated fetal bovine serum (FBS), 2 mM L-glutamine, antibiotic
solution (penicillin/streptomycin 100 U/mL and 100 µg/mL) (All Sigma-Aldrich, St. Louis,
MO, USA). The resulting aspirate was transferred to a test tube with an equal volume of
HBSS with 2% inactivated FBS. The resulting suspension was layered on a Histopaque-1077
density gradient in a 2:1 suspension-gradient ratio and centrifuged for 25 min at 300× g.
The cells of the interphase ring were harvested and diluted with a 5-fold volume of HBSS
with 2% inactivated FBS and washed twice by centrifugation at 250× g for 7–10 min. Cells
were counted in hemocytometer [42,43].
4.9.2. Cultivation of MSCs
Lung mononuclear cells in an amount of 0.5–1.0 × 108 were resuspended in 7 mL
of culture medium warmed to 37 ◦C, consisting of 90% DMEM-LG (Sigma-Aldrich,
St. Louis, MO, USA), 10% inactivated FBS (Sigma-Aldrich, St. Louis, MO, USA), 2 mM L-
glutamine (Sigma-Aldrich, St. Louis, MO, USA), antibiotic solution (penicillin/streptomycin
100 U/mL and 100 µg/mL; Sigma-Aldrich, St. Louis, MO, USA). Then, the cell suspension
was introduced into a culture flask with a vented cap and an area of 25 cm2 (Techno Plastic
Products AG, Trasadingen, Switzerland) and incubated at 37 ◦C, 5% CO2, and 100% air
humidity for 72 h. Then, the supernatant with non-adherent cells was removed, and the
base culture medium was replaced with a new portion. Preliminarily, markers of MSCs
were studied in some of the adherent cells. Subsequent changes of the medium were
made every 3–4 days until 70–90% coverage of the vial surface with cells was achieved,
depending on the group.
After reaching the maximum confluence (70–90% of the total area of the flask), the cell
culture was washed twice with phosphate buffer (Sigma-Aldrich, St. Louis, MO, USA).
The cells were removed from the plastic surface using a 13 mm wide silicone spatula
(Techno Plastic Products AG, Trasadingen, Switzerland). The removed cells were washed
off with PBS (Sigma-Aldrich, St. Louis, MO, USA) for subsequent use (second passage).
The concentration of mononuclear cells during repeated passaging was 0.5–1.0 × 107 in
7 mL of the base culture medium. At the end of the cultivation cycle, the cell culture was
washed twice with phosphate buffer in a culture flask and removed from the surface with
a silicone spatula. A suspension of mononuclear cells was transferred into test tubes and
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centrifuged at 300× g for 5–7 min. The supernatant was replaced with 1–2 mL of the basic
culture medium, the number of mononuclear cells was counted and the immune profile of
MSCs was assessed.
At each change of the base medium and upon reaching the maximum confluence, a
morphological assessment of the state of the cell culture was carried out. The doubling time
(tD) of endothelial and epithelial cells, and fibroblast cells was calculated by the formula:
tD = (log2 × t )/(logNh − logN0) (2)
where N0 is the number of cells during the second change of the medium, Nh is the number
of cells during the studied period of cultivation t [42,43].
4.9.3. Differentiation of Lung MSCs In Vitro
To confirm osteogenic differentiation, cells obtained after long-term cultivation were
transferred into a 6-well culture plate (2.5 × 105 cells/well) in a culture medium containing
90% DMEM-LG (Sigma-Aldrich, St. Louis, MO, USA), 10% FBS (Sigma-Aldrich, St. Louis,
MO, USA), and supplemented with 0.2 mM L-ascorbic acid 2-phosphate (Sigma-Aldrich,
St. Louis, MO, USA), 10 mM β-glycerophosphate (Sigma-Aldrich, St. Louis, MO, USA),
1 × 10−8 M dexamethasone (Sigma-Aldrich, St. Louis, MO, USA), 100 U/mL penicillin,
and 100 µg/mL streptomycin (Sigma-Aldrich, St. Louis, MO, USA). The medium was
changed every 3–4 days. On day 21, the cell culture was washed twice with phosphate
buffer and fixed in 4% formaldehyde (Sigma-Aldrich, St. Louis, MO, USA) for 10 min.
Mineralization of the extracellular matrix was visualized by von Koss staining, which
served as an indicator of osteogenic differentiation.
To study adipogenic differentiation, MSCs were seeded into 6-well culture plates
(2.5 × 105 cells/well) and cultured in a medium containing 90% DMEM-LG (Sigma-Aldrich,
St. Louis, MO, USA), 10% inactivated FBS (Sigma-Aldrich, St. Louis, MO, USA), 100 U/mL
penicillin, and 100 µg/mL streptomycin (Sigma-Aldrich, St. Louis, MO, USA), 0.5 µM
hydrocortisone (Sigma-Aldrich, St. Louis, MO, USA), 60 µM indomethacin (Sigma-Aldrich,
St. Louis, MO, USA), 1 µg/mL insulin (Sigma-Aldrich, St. Louis, MO, USA USA), 0.5 µM
isobutyl-methylxanthine (Sigma-Aldrich, St. Louis, MO, USA, USA). The medium was
changed every 4 days. The complete cultivation cycle was 21 days. Adipogenic differentia-
tion was assessed by the intracellular accumulation of lipids stained with 0.5% Oil Red O
(Sigma-Aldrich, St. Louis, MO, USA).
Granular cultures of MSCs for the study of chondrogenesis were prepared from
4 × 105 cells placed in 15 mL polypropylene tubes (Techno Plastic Products AG, Trasadin-
gen, Switzerland) in a medium of the following composition: 95% DMEM-HG (Sigma-
Aldrich, St. Louis, MO, USA), 1% ITS+3 Liquid Media Supplement (Sigma-Aldrich,
St. Louis, MO, USA), 1% antibiotic solution (penicillin/streptomycin 100 U/mL and
100 µg/mL (Sigma-Aldrich, St. Louis, MO, USA), 100 µg/mL pyruvate soda (Sigma-
Aldrich, St. Louis, MO, USA), 50 µg/mL L-ascorbic acid 2-phosphate (AsAP, Sigma-
Aldrich, St. Louis, MO, USA), 40 µg/mL L-proline (Sigma-Aldrich, St. Louis, MO, USA),
0.1 µM dexamethasone (Sigma-Aldrich, St. Louis, MO, USA), and 10 ng/mL recombinant
human TGF-β1 (Sigma-Aldrich, St. Louis, MO, USA). The cells were cultured for 14 days;
the medium was changed every 3 days. On day 14, the cell granules were removed, fixed in
10% formalin solution for 24 h, and embedded in paraffin. To detect sulfated proteoglycans,
sections of granules were stained with toluidine blue.
Fibroblast differentiation of MSCs was studied in the following medium: 90% DMEM-
HG (Sigma-Aldrich, St. Louis, MO, USA) with fibroblast growth factor 2 µg/mL (Sigma-
Aldrich, St. Louis, MO, USA) supplemented with 10% inactivated FBS (Sigma-Aldrich,
St. Louis, MO, USA), 280 µg/mL L-glutamine (Sigma-Aldrich, St. Louis, MO, USA),
50 µg/mL gentamicin (Serva, Heidelberg, Germany), 10−8 M dexamethasone (Sigma-
Aldrich, St. Louis, MO, USA). The cell concentration was 6 × 105 cells in 2 mL. On the 18th
day cell cultures were fixed in 4% formaldehyde (Pancreas, San Jose, CA, USA) and stained
with the main May-Grunwald stain [42].
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4.9.4. Formation of Fibroblast Colonies by CD45- Cells
After the study of the CD45 marker, the final concentration of the adherent cell ele-
ments of the lungs was adjusted to 0.5 × 106/mL with a liquid nutrient medium of the
following composition: 80% DMEM medium (Sigma-Aldrich, St. Louis, MO, USA), 20%
FBS (Sigma-Aldrich, St. Louis, MO, USA), 280 mg/L L-glutamine (Sigma-Aldrich, St. Louis,
MO, USA), 50 mg/L gentamicin (Sigma-Aldrich, St. Louis, MO, USA), 25 ng/mL fibroblast
growth factor (Sigma-Aldrich, St. Louis, MO, USA). Then, 0.5 mL of the prepared suspen-
sion was placed in plastic 24-well plates (Corning, New York, NY, USA) and incubated in a
CO2 incubator at 37 ◦C, 5% CO2, and 100% air humidity for 7 days. After incubation under
an inverted microscope, the number of colonies was counted. Fibroblast colonies (CFU-F)
meant cell aggregates containing more than 50 cells of fibroblast morphology [42].
4.10. Statistical Analysis
Statistical analysis was performed using SPSS (version 15.0, SPSS Inc., Chicago, IL, USA).
Data were analyzed and presented as means ± standard error of the mean. Statistical
significance was evaluated by Student’s t-test (for parametric data), or Mann–Whitney test
(for nonparametric data) when appropriate. A p-value of less than 0.05 (by two-tailed testing)
was considered an indicator of statistical significance.
5. Conclusions
Our study showed that poloxamer-hyaluronidase, created using electron beam syn-
thesis, has anti-inflammatory and antifibrotic effects in animals with pulmonary fibro-
sis. The positive effect of treatment with pHD is significantly superior to that of native
hyaluronidase, which can be explained by the resistance of poloxamer-hyaluronidase to
the destructive action of various factors. The anti-inflammatory and antifibrotic effects,
polytherapy with spiperone and pHD is superior to monotherapy with pHD and spiperone.
We observed regeneration of endothelial and epithelial cells in this case.
Thus, sequential spiperone administration and destruction of hyaluronic acid by pHD
may be a promising approach for the treatment of patients with IPF.
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